Indianapolis, Ind. – August 02, 2007 - Long-term use of histamine2 receptor antagonists (H2A), one class of drugs that blocks stomach acid, may be associated with cognitive impairment in older African-American adults. According to an Indiana University School of Medicine and Regenstrief Institute study published in August issue of the Journal of the American Geriatrics Society, the risk for showing signs of cognitive impairment is 2.5 times greater for patients using these medications long-term.
These acid blockers, including ranitidine and famotidine, are among the most popular medications prescribed in the United States. More than 16 million prescriptions were dispensed in 2005 and several of these medications are also available over-the-counter. The drugs are sold under brand names such as Axid, Pepcid, Tagamet and Zantac, and are used to treat ulcers, acid reflux and other gastrointestinal disorders.
The five-year observational study included 1,558 cognitively normal African-Americans aged 65 and older. After controlling for other possible factors, nearly 18 percent of H2A users studied exhibited signs of cognitive impairment.
“Taking these medications continuously appears to put older African-Americans at greater risk for the development of cognitive impairment,” said Malaz Boustani, M.D., MPH, lead author of the study. “We need to study this further to determine how acid blockers might be causing or creating this effect and if it occurs only in African-Americans.”
Malaz Boustani, M.D., MPH, is affiliated with the Regenstrief Institute, Inc. in Indianapolis, Indiana. Questions for the author can be directed to Cindy Fox Aisen at firstname.lastname@example.org.
The Journal of the American Geriatrics Society is a comprehensive and reliable source of monthly research and information about common diseases and disorders of older adults. For more information, please visit www.blackwellpublishing.com/jgs.
Wiley-Blackwell was formed in February 2007 as a result of the merger between Blackwell Publishing Ltd. and John Wiley & Sons, Inc.'s Scientific, Technical, and Medical business. Together, the companies have created a global publishing business with deep strength in every major academic and professional field. Wiley-Blackwell publishes approximately 1,250 scholarly peer-reviewed journals and an extensive collection of books with global appeal. For more information on Wiley-Blackwell, please visit www.blackwellpublishing.com or http://interscience.wiley.com.